MGB Biopharma Receives £1.3m Grant Award
Grant to help fund Phase I trial with lead candidate oral MGB-BP-3 for Clostridium difficile
MGB Biopharma, a biopharmaceutical company developing truly novel anti-infectives, announced that it has been awarded a £1.3 million conditional grant from the Technology Strategy Board, the UK’s innovation agency, under its Biomedical Catalyst programme.
The grant will help fund a Phase I trial of the oral formulation of MGB Biopharma’s lead investigational drug candidate, MGB-BP-3 for Clostridium difficile. Approximately 40 subjects are expected to be enrolled into the single centre, double-blind, placebo controlled, crossover Phase I trial to determine the safety and tolerability of single ascending doses of oral MGB-BP-3.
MGB-based anti-infectives have the potential to deliver significant advantages over current approaches including broad, bactericidal activity against multi-resistant Gram-positive and Gram-negative pathogens. In addition to the oral formulation of lead candidate MGB-BP-3, MGB Biopharma is developing an IV formulation for the treatment of Gram-positive hospital-acquired infections. MGB Biopharma’s platform also promises to deliver compounds that are active against certain viruses, fungi and parasites. MGB Biopharma’s anti-infectives are based on its minor groove binder (MGB) technology.
Other news from the department business & finance
